Humoral immunostimulation. VII. Sialic acid masks antigenic sites on an antibody-selected bariant cell line - PubMed (original) (raw)
- PMID: 69664
Humoral immunostimulation. VII. Sialic acid masks antigenic sites on an antibody-selected bariant cell line
W T Shearer et al. J Immunol. 1977 Aug.
Abstract
Variant cell lines (LC1, LC2) obtained by growth of mouse L cells (L) in cytostimulatory and cytotoxic doses, respectively, of rabbit anti-L cell antiserum AL) were found previously to be altered in many ways relative to the parent cell line. A major change was the reduction of those surface membrane antigens that AL recognizes. These cell variants have now been found to have increased membrane sialic acid relative to L. Treatment of intact variant cells with neuraminidase (50 units/ml, 37 degrees C, 1 hr) greatly restored the susceptibility of LC1 to lysis with AL. In the presence of 1/100 dilution of AL and 5% complement the viability indices (1.00 = no cell kill) of untreated and neuraminidase-treated cells were respectively: L 0.10 and 0.03 and LC1 0.91 and 0.40. Neuraminidase-treated LC2 cells retained their resistance to AL. Parallel studies with 125I-ALIgG showed increased binding to neuraminidase-treated LC1 relative to native LC1. These findings suggest that the altered membrane sialic acid content affects the immunologic behavior of this cell variant by masking the original cell surface antibody-binding sites. This represents a possible mechanism for tumors to escape immunologic control.
Similar articles
- Humoral immunostimulation. V. Selection of variant cell lines.
Shearer WT, Parker CW. Shearer WT, et al. J Exp Med. 1975 Nov 1;142(5):1133-49. doi: 10.1084/jem.142.5.1133. J Exp Med. 1975. PMID: 1194850 Free PMC article. - [Analysis of the escape of tumor P1798(SC) from immunologic control in hybrid mice (Balb/c X AKR)F1 (BAF1)].
Ubeira FM, Seoane R, Puentes E, Faro J, Regueiro BJ. Ubeira FM, et al. Rev Esp Oncol. 1982;29(4):711-6. Rev Esp Oncol. 1982. PMID: 6985427 Spanish. - Neuraminidase reversal of resistance to lysis of herpes simplex virus-infected cells by antibody and complement.
Tompkins WA, Seth P, Gee S, Rawls WE. Tompkins WA, et al. J Immunol. 1976 Feb;116(2):489-95. J Immunol. 1976. PMID: 175118 - Antibody and complement modulation of tumor cell growth in vitro and in vivo.
Shearer WT, Parker CW. Shearer WT, et al. Fed Proc. 1978 Aug;37(10):2385-9. Fed Proc. 1978. PMID: 354972 Review. - Bacterial neuraminidase and altered immunological behavior of treated mammalian cells.
Ray PK. Ray PK. Adv Appl Microbiol. 1977;21:227-67. doi: 10.1016/s0065-2164(08)70043-1. Adv Appl Microbiol. 1977. PMID: 403747 Review. No abstract available.
Cited by
- Novel lamprey antibody recognizes terminal sulfated galactose epitopes on mammalian glycoproteins.
McKitrick TR, Bernard SM, Noll AJ, Collins BC, Goth CK, McQuillan AM, Heimburg-Molinaro J, Herrin BR, Wilson IA, Cooper MD, Cummings RD. McKitrick TR, et al. Commun Biol. 2021 Jun 3;4(1):674. doi: 10.1038/s42003-021-02199-7. Commun Biol. 2021. PMID: 34083726 Free PMC article. - Skin test reactivity and number of siblings.
von Mutius E, Martinez FD, Fritzsch C, Nicolai T, Reitmeir P, Thiemann HH. von Mutius E, et al. BMJ. 1994 Mar 12;308(6930):692-5. doi: 10.1136/bmj.308.6930.692. BMJ. 1994. PMID: 8142793 Free PMC article. - Intratumor immunologic heterogeneity.
Miller FR. Miller FR. Cancer Metastasis Rev. 1982;1(4):319-34. doi: 10.1007/BF00124215. Cancer Metastasis Rev. 1982. PMID: 6192904 Review. - [Glycoproteins: their biological and clinical significance. II (author's transl)].
Köttgen E, Bauer C, Reutter W, Gerok W. Köttgen E, et al. Klin Wochenschr. 1979 Mar 1;57(5):199-214. doi: 10.1007/BF01477489. Klin Wochenschr. 1979. PMID: 431030 German. No abstract available.